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S308 Poster Session IIcells on day 14 after allo-BMT, revealed that these cells displayed sub-
stantial levels of cell-surface P-selectin ligands as defined by positive
staining with recombinant P-selectin-IgG-Fc fusion protein at levels
similar to those foundonWTTcells, suggesting that althoughabsence
of P-selectin on host tissues may ameliorate GVHD, multiple donor
leukocyte P-selectin ligands interact meaningfully with P-selectin.
Our studies suggest that P-selectin may be required for trafficking
into inflamed tissues but not SLO, and that donor T cells may utilize
multiple P-selectin ligands apart from PSGL1 to interact with P-se-
lectin and traffic into inflamed tissues during GVHD.409
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Preparative regimens incorporating antithymocyte globulin
(ATG) have been shown to decrease the incidence of both acute
and chronic graft-versus-host disease (aGVHD and cGVHD). It is
less clearwhether priorATGinfluences the patternof onset, duration
of treatment and graft-versus-malignancy(GVM) effect of cGVHD.
Between 1999 and 2008, 538 patients (pts) with hematologic malig-
nancy aged 18–66 years (median 46) received blood cell (n5 440,
82%) or marrow transplants after conditioning with Flu 50 mg/m2
daily  5 and IV Bu 3.2 mg/kg daily  4. Two hundred and thirty-
four (43%) had additional total body irradiation (TBI) 200 cGy 2.
GVHD prophylaxis was cyclosporin A, methotrexate and Thymo-
globulin (Genzyme) 4.5 mg/kg total dose. Donors werematched sib-
lings in 299 (56%), mismatched related in 27(5%), 10/10 matched
unrelated in 146 (27%) and mismatched unrelated in 66(12%).
Two hundred and fifty-six pts (48%) had low-risk (LR, acute leuke-
mia CR1/CR2, CML CP1) disease. Incidence of aGVHD grade II-
IV, aGVHD grade III-IV and cGVHD (at 2 years) was 24%, 10%
and 56% respectively. Of 474 pts surviving .100days, 371 (78%)
had no or grade I aGVHD, 167 (45%) of whom developed cGVHD.
Of the 103 pts with prior grade II-IV aGVHD, 4 died before d126 of
late effects of aGVHD (and are excluded from the analysis of the no
cGVHD group), 17 survived without cGVHD, 21 developed
cGVHD after discontinuing treatment for aGVHD (‘‘quiescent’’
cGVHD) of whom 2 (10%) died without relapse. Sixty-one devel-
oped cGVHD before completing treatment for aGVHD grade II-
IV, defined as ‘‘progressive’’ cGVHD (pcGVHD) for the purpose
of this study. There were therefore 188 pts with ‘‘non-progressive’’
cGVHD (npcGVHD) (167 de novo plus 21 ‘‘quiescent’’) and 221
with no cGVHD. At follow-up of survivors of 14–124 months (me-
dian 60) 5 year outcomes (%) were as follows:(see table).
All pcGVHDpts and 143 npcGVHDpts (76%) required systemic
therapy. Median time on treatment was 495 days compared with 286
days (p5 0.07), with 79% and 83% respectively being off immuno-
suppression by 3 years from onset of cGVHD. Despite a relatively
low incidence of aGVHD with this regimen about 60% of those
who do develop grade II-IV aGVHD and live100 days develop
pcGVHDwith a significantly higher risk ofNRM than other pts. Be-
cause of less relapse and equivalent NRM, OS and DFS are better in
pts with npcGVHD than those with no cGVHD. The challenge re-
mains to prevent aGVHD without sacrificing the GVM effect of
cGVHD.5 years outcomes in relation to cGVHD
npcGVHD(%) No cGVHD(%) pcGVHD(%) p value
OS 68*† 61* 50† *0.02, † 0.006
DFS 66*† 55* 42† *0.003,† 0.004
NRM 8* 12† 42*† *†\0.0001
Relapse 28* 39*† 28† *0.006, †0.02410
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Background: Bronchiolitis obliterans syndrome (BOS) is a rare and
serious complication of allogeneic HCT, requiring long courses of
systemic corticosteroids that are often associated with adverse conse-
quences. Thus, novel therapies to reduce corticosteroid exposure
may be beneficial.
Hypothesis: Combined treatment with fluticasone, azithromycin
and montelukast (FAM), three agents with anti-inflammatory and
antifibrotic properties, all with low toxicity, will reduce the overall
six-month exposure to corticosteroids in BOS patients.
Methods: Between June 2008 and the present, we reviewed 8 pa-
tients who met NIH criteria for newly diagnosed BOS and were
treated with FAM therapy indefinitely and a 2-week pulse of high
dose (1 mg/kg/day) prednisone followed by a rapid taper. These
patients were compared with 14 historical controls identified
from a pre-existing database, who also met NIH criteria, and re-
ceived high dose prednisone therapy followed by a standard taper.
The total prednisone exposure (median values and interquartile
ranges) six months after diagnosis and interval change in FEV1 at
three, and/or six months after BOS diagnosis were compared.
FEV1 was reported as percent predicted with preference given to
post-bronchodilator values. FEV1 change was defined as change
in FEV1 from diagnosis to three or six months, depending on
pulmonary function test availability. Treatment failure was defined
as a decline in FEV1$ 10% and clinical worsening of symptoms
resulting in increase in prednisone dose within six months of
diagnosis.
Results: The median six month prednisone exposure for the FAM-
treated patients was 1819 mg [25th percentile5 0 mg; 75th percenti-
le5 4036 mg] compared to 7163 mg [25th percentile5 6551 mg;
75th percentile5 7829 mg] in the control group. The median
FEV1 change in the FAM group was 2% [25
th percentile5 -7%;
75th percentile5 4%] compared to 1% [25th percentile5 -4%;
75th percentile5 5%] in the control group. There was one treatment
failure in the FAM group (12%) compared to one in the control
group (7%).
Conclusions:The total six month prednisone exposure in a group of
eight patients treatedwith FAMtherapywas one quarter that of a ret-
rospective group of BOS patients who were treated with standard
prednisone therapy, with minimal change in median FEV1 in both
groups. FAM therapy may allow for less total exposure to corticoste-
roids and may avert some complications associated with steroid
therapy.411
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It is well recognized that T cells are the principal orchestrators
of graft versus host disease (GVHD). Historically, IFN-g produc-
ing Th1 cells have been implicated in the pathogenesis of acute
GVHD (aGVHD) whereas Th2 cells have been thought to be in-
volved in the pathogenesis of chronic GVHD (cGVHD). The re-
cent discovery of a distinct lineage of IL-17 producing Th17
cells, thought to be the major perpetrators in a number of inflam-
matory and autoimmune disorders, has prompted re-evaluation of
the Th1/Th2 paradigm of GVHD. Studies in IL-17 deficient
mice have shown conflicting results with IL-17 having both a pro-
tective or deleterious effect, whereas transplantation of purified
Th17 cells causes GVHD-related tissue damage with a predilection
for the skin and lungs. In this study we aimed to determine whether
Th17 cells play a role in the pathogenesis of human GVHD. 37
